Novo Nordisk further slashes prices of Ozempic, Wegovy in India to better compete as generics enter

Novo Nordisk cut prices for Ozempic by up to 36% and Wegovy by up to 48% to better compete as local drugmakers flood the market with cheaper generics. The move is designed to defend market share but will likely put pressure on revenue and margins for its flagship diabetes and weight-loss franchises.

Analysis

Novo Nordisk cut prices for Ozempic by up to 36% and Wegovy by up to 48% to better compete as local drugmakers flood the market with cheaper generics. The move is designed to defend market share but will likely put pressure on revenue and margins for its flagship diabetes and weight-loss franchises.